Trial · NCT01330966
Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
NCT01330966, Phase 2, Completed, Emerald Clinical Inc.; results first posted 2020-02-12
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma. Trials, record NCT01330966. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT01330966
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study of Pazopanib in the Treatment of Surgically Unresectable or Metastatic Chondrosarcoma
- NCT number
- NCT01330966
- Status
- Completed
- Phases
- Phase 2
- Enrollment
- 47 participants, actual
- Lead sponsor
- Emerald Clinical Inc.
- Conditions
- Chondrosarcoma, Metastatic Chondrosarcoma
- Interventions
- pazopanib
- First posted
- 2011-04-07
- Last updated
- 2023-03-10
- Results first posted
- 2020-02-12
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Disease Control at Week 16 | Assessed at week 16 of study treatment | Disease control at week 16 defined as complete response (CR), Disappearance of all target lesions; plus partial response (PR), At least a 30% decrease in the sum of diameters of the target lesions taking as reference the Baseline sum diameters; plus stable disease (SD), Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD taking as reference the smallest sum diameters while on the study; where tumor response is defined by RECIST (Response Evaluation Criteria in Solid Tumors) guidelines version 1.1. Repeat radiologic imaging is performed after every 2 cycles of treatment (approximately every 8 weeks). |
| Secondary | Progression Free Survival (PFS) | Cycle 1 day 1 until the subject experiences disease progression | The time origin for PFS will be cycle 1 day 1. Repeat radiologic imaging will be conducted after every 2 cycles of treatment (approximately every 8 weeks). No upper limits of duration of assessment are identified or defined in the protocol. |
| Secondary | Overall Survival (OS) | Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent | The time origin for OS will be cycle 1 day 1. Subjects will be followed until 6 months after end of treatment, lost to follow-up, or withdrawal of consent. No upper limits of duration of assessment are identified or defined in the protocol. |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Disease Control at Week 16 | Assessed at week 16 of study treatment | Tumor responses were evaluable in 42 out of 47 patients; 5 patients discontinued prior to the first tumor assessment. | Percentage of CR+PR+SD | NUMBER |
| SECONDARY | Progression Free Survival (PFS) | Cycle 1 day 1 until the subject experiences disease progression | months | MEDIAN | |
| SECONDARY | Overall Survival (OS) | Cycle 1 day 1 until 6 months after end of treatment, is lost to follow-up, or withdraws consent | months | MEDIAN |
Source ClinicalTrials.gov
Results by group3
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Disease Control at Week 16 | Pazopanib | 43 | 95% Confidence Interval 28 to 58 | Percentage of CR+PR+SD | |
| Progression Free Survival (PFS) | Pazopanib | 7.9 | 95% Confidence Interval 3.7 to 12.6 | months | |
| Overall Survival (OS) | Pazopanib | 17.6 | 95% Confidence Interval 11.3 to 35.0 | months |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Pazopanib | 47 | |
| Overall Study | COMPLETED | Pazopanib | 42 | |
| Overall Study | NOT COMPLETED | Pazopanib | 5 |
Source ClinicalTrials.gov
Adverse events73
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| other | Thrombocytopenia | Blood and lymphatic system disorders | Pazopanib | 2 | 47 | 2 |
| other | Sinus bradycardia | Cardiac disorders | Pazopanib | 4 | 47 | 4 |
| other | Hyperthyroidism | Endocrine disorders | Pazopanib | 2 | 47 | 2 |
| other | Hypothyroidism | Endocrine disorders | Pazopanib | 6 | 47 | 6 |
| other | Abdominal pain upper | Gastrointestinal disorders | Pazopanib | 2 | 47 | 2 |
| other | Constipation | Gastrointestinal disorders | Pazopanib | 11 | 47 | 13 |
| other | Diarrhoea | Gastrointestinal disorders | Pazopanib | 22 | 47 | 43 |
| other | Dyspepsia | Gastrointestinal disorders | Pazopanib | 5 | 47 | 5 |
| other | Nausea | Gastrointestinal disorders | Pazopanib | 24 | 47 | 35 |
| other | Oral dysaesthesia | Gastrointestinal disorders | Pazopanib | 2 | 47 | 2 |
1 to 10 of 73Source ClinicalTrials.gov
See all 73 adverse eventsAdverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Pazopanib | 1 | 47 |
| Total, other adverse events | Pazopanib | 39 | 47 |
| Total, serious adverse events | Pazopanib | 19 | 47 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT01330966
GET https://conductscience.org/api/trials/v1/NCT01330966/events?page=2